| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H15ClN2OS |
| Molecular Weight | 318.821 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC1=CC2=C(S1)N(C)C(=O)CN=C2C3=C(Cl)C=CC=C3
InChI
InChIKey=CHBRHODLKOZEPZ-UHFFFAOYSA-N
InChI=1S/C16H15ClN2OS/c1-3-10-8-12-15(11-6-4-5-7-13(11)17)18-9-14(20)19(2)16(12)21-10/h4-8H,3,9H2,1-2H3
| Molecular Formula | C16H15ClN2OS |
| Molecular Weight | 318.821 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Clotiazepam is a compound of the benzodiazepine class. The drug was developed in Japan and approved for the treatment of insomnia, anxiety and before anesthesia. Clotiazepam was marketed worlwide under different names, however, currently it is available only in South America under the name Neuroval and presumably in Japan. Clotiazepam exerts its action by binding and activating GABA-A receptors.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Treatment of anxiety: the usual dose in adults is 1 tablet (10 mg) 1 to 3 times a day for 8-12 weeks. Treatment of insomnia: the usual adult dose is 1 tablet (10 mg) to 2 tablets (20 mg) administered at night, before bedtime. The duration of treatment is usually 2-4 weeks.
Route of Administration:
Oral
